Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients with Localized Prostate Cancer after Radical Prostatectomy

This early phase I trial studies the feasibility of a daily, long-term intermittent fasting routine in preventing or delaying a rise in prostate specific antigen (PSA) levels in patients with prostate cancer that has not spread to other parts of the body (localized) and who have undergone radical prostatectomy. PSA is a protein produced by both normal and cancer cells. Following a daily fasting routine after treatment for prostate cancer may lower the risk of patients' PSA level rising above 0.4 ng/mL, which is also called PSA-recurrence. A PSA-recurrence can sometimes mean that the disease has returned and/or progressed.

Additional locations may be listed on ClinicalTrials.gov for NCT04288336.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase O

Trial Typeprevention

Lead OrganizationMayo Clinic in Rochester

Principal InvestigatorRobert Jeffrey Karnes

• Primary ID19-006675
• Secondary IDsNCI-2020-00832, MC2052
• ClinicalTrials.gov IDNCT04288336